<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-205 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-205</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-205</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-11.html">extraction-schema-11</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <p><strong>Paper ID:</strong> paper-308d8504e83610df71690c0b8f4c1b629e03a3c5</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/308d8504e83610df71690c0b8f4c1b629e03a3c5" target="_blank">Thymoma and autoimmunity</a></p>
                <p><strong>Paper Venue:</strong> Cellular & Molecular Immunology</p>
                <p><strong>Paper TL;DR:</strong> The current scientific evidence detailing the various interactions between thymoma and autoimmune diseases, including myasthenia gravis, systemic lupus erythematosus, inappropriate antidiuretic hormone secretion, pure red cell aplasia, pernicious anemia, pemphigus and autoimmune thyroid diseases is compiled.</p>
                <p><strong>Cost:</strong> 0.015</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e205.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e205.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Immature T-cell theory</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Immature thymoma-derived T-cell export (escape theory)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Thymoma generates and exports immature thymocytes that bypass medullary negative selection, leading to peripheral autoreactive T cells; supported by histologic immaturity markers and high intratumoral proliferation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>WHO types B1 and B2 emphasized (lymphocyte-rich/cortical features) with abundant CD4+/CD8+ double-positive thymocytes and evidence of cortical-like organization; general review of WHO and Masaoka classifications referenced.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>Myasthenia gravis (most common), plus myositis/myocarditis (anti-ryanodine receptor), neuromyotonia, antibodies to titin/voltage-gated calcium channels; other associations: systemic lupus erythematosus (SLE), pure red cell aplasia (PRCA), autoimmune cytopenias (thrombocytopenia, neutropenia), pemphigus/paraneoplastic pemphigus, bullous pemphigoid, pernicious anemia, autoimmune thyroid disease, dermatomyositis, encephalitis, SIADH; frequent co-occurrence of multiple autoimmune diseases in same patient.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>Review reports: 75% of MG patients have thymic abnormality (85% hyperplasia, 15% thymoma); ~30% of thymoma patients are diagnosed with autoimmune conditions either concurrently or post-thymectomy; up to 50% of thymoma patients diagnosed with two autoimmune diseases in some series; SLE comorbidity estimated 1.5–2% in clinical epidemiology and up to 10% in thymus biopsy series; PRCA coexists in ~5% of thymomas; specific large cohort: Okumura et al. N=467 thymectomized MG patients cited.</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>Indirect histologic and cellular evidence consistent with defective central tolerance: presence of abundant cortical-like thymocytes in thymomas and suggestion that thymocytes fail to transit medullary zones where negative selection occurs (the 'escape' concept). Neoplastic epithelial cells show slightly reduced HLA-DR expression (reported), which could impair antigen presentation for positive/negative selection. The review does not report direct measurements of AIRE or Fezf2, nor direct assays of tissue-restricted antigen expression or transcriptomic profiling in thymoma medullary epithelial cells.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Reported findings: thymomas (especially B1/B2) contain many CD4+/CD8+ double-positive immature thymocytes; lower counts of mature CD4+ T cells in thymoma tissue versus normal thymus; high intratumoral proliferation (Ki67-positive cells 35–80% in Chilosi et al. immunostaining); suggestion of export of autoreactive/immature T cells to periphery. Cited evidence includes immunohistochemistry (Ki67, TdT and other immaturity markers) and clinical flow/cell-subset studies (ref. Hoffacker et al.). No TCR-sequencing or clonality/TCR repertoire deep-sequencing data reported in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>The review notes the central role of thymic generation of regulatory T cells in tolerance and references work implicating altered Treg biology (citation of Chen et al. on accelerated FoxP3+ differentiation via IL-7 pathway), but provides no direct quantitative data from thymoma patients on FOXP3+ cell counts, suppressive function assays, or correlation between Treg alterations and clinical autoimmunity in thymoma; overall evidence is limited and indirect.</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>Strong clinical/humoral associations: AChR autoantibodies in MG (central), striational antibodies including titin and anti-ryanodine receptor, voltage-gated/calpium channel autoantibodies; intrathymic germinal centers are characteristic of some thymomas and are implicated in intrathymic autoantibody generation; observed reduction in anti-AChR titers after thymectomy supports intrathymic contribution to autoantibody production. In PRCA, thymomas showed small germinal centers and bone marrow lymphoid aggregation, linking cellular and humoral alterations. Methods reported are serology for autoantibodies and histology for germinal centers.</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>Mentioned but not deeply analyzed: case reports link thymoma with hypogammaglobulinemia and pernicious anemia; the review cites examples (Good syndrome-like presentations) but does not provide prevalence estimates or mechanistic detail on how humoral immunodeficiency coexists with autoimmunity in these patients.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>Limited data in review. Background thymic factors (thymolin, thymopoietin, thymosin alpha-1) are noted as regulators of thymic function, but specific cytokine/chemokine changes or checkpoint molecule expression in thymoma microenvironment are not described. Intratumoral germinal centers are highlighted as a microenvironmental feature linking T–B interactions.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>Reported molecular associations: slightly reduced HLA-DR expression on neoplastic thymic epithelial cells compared with normal thymus; HLA associations (HLA-A24, HLA-B8) noted as predictive factors for MG and correlated with thymoma development in cited studies (Machens et al.). The review discusses the concept that high proliferation rates in cortical thymocytes increase chances of genetic mutation but presents no somatic mutation or AIRE-pathway molecular data.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>Autoimmunity may present before, concurrently with, or after thymoma diagnosis. Examples: MG frequently co-occurs with thymoma; some autoimmune diseases (e.g., SLE) have remitted after thymectomy, while in other reports SLE appeared after thymectomy—indicating complex temporality. Okumura et al. reported that pre-thymectomy anti-AChR antibody levels may predict post-thymectomy MG. Thymectomy often improves thymoma-associated MG (antibody titer falls) and removal of thymoma has been associated with regression of paraneoplastic dermatoses in case reports.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>Thymectomy: clinical improvement and reduction in anti-AChR titers in thymoma-associated MG; thymomectomy led to regression of pemphigus in case reports and remission of steroid-resistant SLE in select cases, but paradoxically SLE has also appeared after thymectomy in other reports. No randomized trials; data derive from case series, cohort observations, and case reports. Immunotherapies and other systemic treatments are mentioned in context but without systematic outcome data.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>Tumor-induced disruption of thymic architecture/progression (especially cortical expansion and failure to transit medulla) → export of immature/autoreactive T cells that have not undergone medullary negative selection → peripheral initiation of autoimmune cascades; intrathymic germinal centers and aberrant CD4 help then drive B-cell autoantibody production.</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>Key numbers reported in review: Ki67+ intratumoral proliferation 35–80% (Chilosi et al.); 75% of MG patients have thymic abnormalities (85% hyperplasia, 15% thymoma); Okumura et al. cohort of 467 MG thymectomized patients showing correlation of thymoma and MG; ~30% of thymoma patients have autoimmune conditions; PRCA coexists with thymoma in ~5%; reductions in anti-AChR titers observed after thymectomy (Soltys et al.). Presence of CD4+/CD8+ double-positive thymocytes in B1/B2 thymomas is reported.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>No direct molecular readouts of central tolerance machinery (AIRE/Fezf2) are provided in this review; some autoimmune conditions have appeared or worsened after thymectomy, arguing against a simple uni-directional causal model; association data may be confounded by referral/selection bias (MG cohorts undergoing thymectomy), and heterogeneity across thymoma subtypes and patient series complicates simple generalization. The review acknowledges that precise mechanisms remain unelucidated.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>This entry synthesizes findings from a narrative review of case reports, case series, cohort studies and immunohistochemical analyses cited in the paper. Key cited primary studies include Okumura et al. (N=467 thymectomized MG patients), Chilosi et al. (immunohistochemical Ki67 study), Hoffacker et al. (blood T-cell subset alterations), and others (case reports and small series for SLE, PRCA, pemphigus).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>Predominantly observational/case-based evidence with heterogeneous populations and methods; limited mechanistic molecular data (no AIRE/Fezf2 measurements reported), lack of longitudinal controlled trials, potential confounding by MG cohorts (referral bias), and sparse functional validation of exported thymoma-derived T cell autoreactivity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Thymoma and autoimmunity', 'publication_date_yy_mm': '2011-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e205.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neoplastic--genetic theory</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoplastic and genetic alteration hypothesis linking thymoma to autoimmunity</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>High proliferation and genetic aberrations in thymoma epithelial and thymocyte compartments alter antigen presentation and selection, promoting autoreactivity; includes altered HLA expression and possible mutational contributions to defective selection.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>General thymoma pathology discussed; review notes genetic differences in neoplastic epithelial cells compared with normal thymus and links certain HLA subtypes to thymoma development and MG (HLA-A24, HLA-B8).</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>Associated autoimmune syndromes include MG (with AChR and other muscle autoantibodies), SLE, PRCA, pemphigus, autoimmune cytopenias and others as in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>See Immature T-cell theory entry; review cites HLA associations as predictive factors for MG in thymoma patients (Machens et al.), but no effect sizes/odds ratios provided in text beyond qualitative associations.</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>Molecular evidence reported: reduced expression of HLA-DR on neoplastic epithelial cells compared with normal thymus (suggested to affect positive selection); no direct data reported on AIRE, Fezf2, or antigen-processing machinery in thymoma medullary epithelial cells within the review.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Argument that increased proliferation in cortical thymocytes raises mutation risk and self-reactivity; thymocytes from cortical hyperproliferative areas show self-reactivity (cited conceptually). No high-resolution TCR repertoire or clonality data presented.</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>The review frames Treg development as a thymic function that may be impaired indirectly by neoplastic changes, but provides no direct measurements of Treg numbers/functions tied to genetic alterations in thymoma.</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>Implicit in the model: neoplastic genetic changes enable export of self-reactive T cells which then provide help to B cells, promoting autoantibody production (AChR, titin, etc.); intratumoral germinal centers support local B-cell activation.</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>Not specifically addressed under the neoplastic-genetic theory in the review; Good syndrome mentioned elsewhere but without genetic data.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>Genetic/neoplastic changes in epithelial cells may alter antigen presentation and microenvironmental cues (e.g., HLA-DR downregulation), but detailed cytokine/immune-checkpoint alterations are not described.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>Reported associations: reduced HLA-DR expression on neoplastic epithelial cells; HLA-A24 and HLA-B8 associated with MG and correlated with thymoma in cited studies (Machens et al.). The review hypothesizes higher mutation risk in hyperproliferating cortical thymocytes but supplies no somatic mutation datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>Genetic associations are proposed to underlie observed correlations between thymoma presence and MG; review references cohorts linking HLA subtypes and thymoma but does not provide temporality beyond association.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>No targeted genetic interventions discussed. Clinical interventions (thymectomy) sometimes reduce autoantibody titers, consistent with tumor-origin antigen presentation, but also can precede new autoimmune phenomena in some reports.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>High proliferation in thymoma cortical compartments increases mutational/genetic abnormalities and reduces normal HLA-DR-mediated antigen presentation by neoplastic epithelial cells, impairing positive/negative selection and enabling autoreactive T-cell emergence that drives autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>Evidence cited: reduced HLA-DR expression on thymoma epithelial cells (qualitative); association of HLA-A24/HLA-B8 with MG and increased thymoma development (Machens et al.); observations that cortical areas with increased proliferation show self-reactivity (theoretical/cited). No quantitative mutation burden or molecular pathway data provided.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>Lack of direct somatic mutation or transcriptomic data in review; absence of AIRE/Fezf2 measures leaves alternative central-tolerance defects unexplored; associations with HLA may reflect population linkage rather than causal tumor-derived changes.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>The review synthesizes immunohistochemical and HLA-association studies (e.g., Machens et al. for HLA correlations) and theoretical considerations about proliferation and mutation risk; primary data are from small histologic/immunogenetic studies rather than large molecular sequencing efforts.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>Speculative linkage between proliferation and mutational causation without sequencing data; HLA associations reported but effect sizes not provided in review; overall hypothesis lacks direct molecular/genetic validation within cited literature as summarized.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Thymoma and autoimmunity', 'publication_date_yy_mm': '2011-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e205.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Combined cellular-humoral deregulation theory</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Two-step cellular-to-humoral deregulation model</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Model proposes thymoma exports autoreactive CD8 (and CD4) T cells that initiate autoimmune damage, then a secondary step involves CD4 T-cell activation of B cells and intrathymic germinal centers to produce autoantibodies, linking cellular autoreactivity to humoral autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>General; model emphasized for thymomas that contain intratumoral germinal centers and abundant immature thymocytes (e.g., WHO B subtypes), but no strict subtype-stage stratification provided beyond references to B1/B2 thymomas.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>Explains humoral-mediated diseases such as MG (AChR antibodies, titin, ryanodine receptor), pemphigus, and SLE-like presentations as downstream of initial T-cell–driven processes; also accounts for T-cell-mediated conditions like PRCA.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>Qualitative model; prevalence values cited elsewhere in review apply (MG-thymoma associations, ~30% thymoma with autoimmune conditions, PRCA ~5%). No additional quantitative risk estimates specific to the two-step model.</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>Supports notion that failure of central tolerance (escape of autoreactive T cells) is first step; evidence cited includes abundant immature thymocytes, failure to undergo medullary selection, and histologic presence of intrathymic germinal centers facilitating B-cell activation. No direct demonstration of defective antigen presentation pathways (AIRE/Fezf2) is given.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Cited observations: export of autoreactive T cells presumed; abnormal peripheral T-cell subset composition in thymoma patients referenced (Hoffacker et al.); lack of detailed repertoire sequencing data in review.</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>Model implies defective tolerance and possibly impaired regulatory T-cell control, but the review does not present direct measures showing Treg deficiency or dysfunction specifically mediating the stepwise process.</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>Explicit support: intrathymic germinal centers characteristic of some thymomas are proposed to be sites where exported/autochthonous T cells help B cells to produce autoantibodies; clinical evidence includes decreased anti-AChR titers after thymectomy and presence of disease-specific autoantibodies (titin, ryanodine receptor, VGCC).</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>Not a central focus of this model. The coexistence of humoral deficiency and autoimmunity (Good syndrome) is acknowledged elsewhere but not reconciled mechanistically here.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>Intratumoral germinal centers and local T–B interactions emphasized as critical microenvironmental features enabling the transition from cellular to humoral autoimmunity; specific cytokine mediators are not detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>No new genetic markers specified for this two-step model beyond general HLA and HLA-DR observations noted in other theories.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>Explains clinical patterns where cellular autoimmune features (e.g., T-cell–mediated cytopenias) and humoral features (e.g., MG antibodies) coexist or sequentially appear; thymectomy can interrupt intrathymic germinal center activity and reduce autoantibody titers, consistent with second-step interruption.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>Thymectomy reducing anti-AChR titers and improving MG supports the model's second-step B-cell involvement; case reports of autoimmune dermatoses regressing after thymoma resection further support intratumoral B-cell contribution. No controlled intervention studies isolating the two steps.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>Causal chain: thymoma produces/export immature or autoreactive T cells (step 1) → these T cells either directly cause tissue damage or provide help to intratumoral or peripheral B cells (step 2) → B-cell activation and intratumoral germinal centers generate disease-specific autoantibodies that mediate humoral autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>Observed reduction in anti-AChR titers after thymectomy (Soltys et al.); presence of intrathymic germinal centers in thymoma histology; clinical co-occurrence of cellular and humoral autoimmune syndromes in same thymoma patients; case reports of autoimmune disease remission following thymoma resection.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>Some autoimmune diseases arise or worsen after thymectomy (e.g., SLE in some reports), arguing that removal of thymic tissue does not uniformly reduce autoimmunity and that peripheral or systemic factors may sustain or initiate autoimmunity independently. Lack of mechanistic dissection distinguishing exported T-cell effects from peripheral autoimmunity limits causal certainty.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>Model is proposed in this narrative review and supported by cited clinical cohorts, case reports, serologic studies, and histopathology reports (intrathymic germinal centers). Primary data include serology (autoantibody titers pre/post thymectomy), histology, and observational clinical outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>Model is biologically plausible and supported by correlative clinical and histologic data, but lacks experimental validation (e.g., functional assays proving exported thymoma-derived T cells are autoreactive and drive B-cell activation), and relies on heterogeneous case-series and case reports.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Thymoma and autoimmunity', 'publication_date_yy_mm': '2011-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease <em>(Rating: 2)</em></li>
                <li>Immunohistochemical evidence of active thymocyte proliferation in thymoma. Its possible role in the pathogenesis of autoimmune diseases <em>(Rating: 2)</em></li>
                <li>Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis <em>(Rating: 2)</em></li>
                <li>Correlation of thymic pathology with HLA in myasthenia gravis <em>(Rating: 2)</em></li>
                <li>The role of T-cells in the initiation of autoantibody responses in thymoma patients <em>(Rating: 1)</em></li>
                <li>Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>